Plasma and Aqueous Humor Angiotensin-Converting Enzyme Levels in Patients with Diabetic Retinopathy

REFERENCES

• Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457–10461.
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Ingelfinger JR, Pratt RE. Regulation of tissue renin and angiotensin gene expressions. J Cardiovasc Pharmacol 1986;8:S11–S16.
   PubMed Web of Science ®Google Scholar
• Paul M, Wagner J, Dzau VJ. Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest 1993;91:2058–2064.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Krum H, Wilkinson-Berka J, et al. The renin-angiotensin system and the long-term complications of diabetes: Pathophysiological and therapeutic considerations. Diabet Med 2003;20:607–621.
   PubMed Web of Science ®Google Scholar
• Danser AH, Derkx FH, Admiraal PJ, et al. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 1994;35:1008–1018.
   PubMed Web of Science ®Google Scholar
• Okada Y, Yamanaka I, Sakamoto T, et al. Increased expression of angiotensin-converting enzyme in retinas of diabetic rats. Jpn J Ophthalmol 2001;45:585–591.
   Google Scholar
• Otani A, Takagi H, Oh H, et al. Angiotensin II-stimulated vascular endothelial growth factor expression in bovine retinal pericytes. Invest Ophthalmol Vis Sci 2000;41:1192–1199.
   PubMed Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Nakanishi Y, et al. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2002;86:311–315.
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study Research Group, ETDRS Report Number 10.Ophthalmology 1991;98:786–806.
   PubMed Web of Science ®Google Scholar
• Holmguist B, Bünning P, Riodan JF. A continuous spectrophotometric assay for angiotensin converting enzyme. Anal Biochem 1979;95:540–548.
   Google Scholar
• Chaturvedi N, Fuller JH, Pokras F, et al. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: The influence of ACE inhibition. Diabet Med 2001;18:288–294.
   PubMed Web of Science ®Google Scholar
• O’Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997;100:678–684.
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Eng J Med 1993;329):1456–1462.
   PubMed Web of Science ®Google Scholar
• Zhang JZ, Xi X, Gao L, et al. Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy. Curr Eye Res 2007;32:883–889.
   PubMed Web of Science ®Google Scholar
• The EUCLID Study Group, Chaturvedi N. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997;349:1787–1794.
   Google Scholar
• Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Eng J Med 2009;361:40–51.
   PubMed Web of Science ®Google Scholar
• Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomized, placebo-controlled trials. Lancet 2008;372:1394–1402.
   PubMed Web of Science ®Google Scholar
• Sjølie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomized placebo-controlled trial. Lancet 2008;372:1385–1393.
   PubMed Web of Science ®Google Scholar
• Danser AHJ, Van den Dorpel MA, Deinum J, et al. Renin, prorenin and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160–167.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Eng J Med 1994;331:1480–1487.
   PubMed Web of Science ®Google Scholar
• Ishizaki E, Takai S, Ueki M, et al. Correlation between angiotensin-converting enzyme, vascular endothelial growth factor, and matrix metalloproteinase-9 in the vitreous of eyes with diabetic retinopathy. Am J Ophthalmol 2006;141:129–134.
   PubMed Web of Science ®Google Scholar
• Gilbert RE, Kelly DJ, Cox AJ, et al. Angiotensin converting enzyme inhibition ameliorates retinal over expression of vascular endothelial growth factor and hyper permeability in experimental diabetes. Diabetologia 2000;43:1360–1367.
   PubMed Web of Science ®Google Scholar
• Moravski CJ, Kelly DJ, Cooper ME, et al. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension 2000;36:1099–1104.
   PubMed Web of Science ®Google Scholar
• Feman SS, Mericle RA, Reed GW, et al. Serum angiotensin converting enzyme in diabetic patients. Am J Med Sci 1993;305:280–284.
   PubMed Web of Science ®Google Scholar
• Hogeboom van Buggenum IM, Polak BC, Reichert-Thoen JW, et al. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Diabetologia 2002;45:203–209.
   PubMed Web of Science ®Google Scholar
• Otani A. Angiotensin II potentiates vascular endothelial growth factor–induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res 1998;82:619–628.
   PubMed Web of Science ®Google Scholar
• Maruichi M, Oku H, Takai S, et al. Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: A possible involvement of chymase in the pathogenesis of macular hole patients. Curr Eye Res 2004;29:321–325.
   PubMed Web of Science ®Google Scholar
• Tikellis C, Jonhston CI, Forbes JM, et al. Identification of angiotensin converting enzyme 2 in the rodent retina. Curr Eye Res 2004;29:419–427.
   PubMed Web of Science ®Google Scholar
• Kramkowski K, Mogielnicki A, Buczko W. The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 2006;57:529–539.
   PubMed Web of Science ®Google Scholar
• Vaajanen A, Luhtala S, Oksala O, et al. Does the renin-angiotensin system also regulate intra-ocular pressure? Ann Med 2008;40:418–427.
   PubMed Web of Science ®Google Scholar
• Luhtaha S, Vaajanen A, Oksala O, et al. Activities of angiotensin-converting enzymes ACE1 and ACE2 and inhibition by bioactive peptides in porcine ocular tissues. J Ocul Pharmacol Ther 2009;25:23–28.
   Google Scholar